Antibodypedia Newsletter
Hello Antibodypedia user,
This is an update of the current status of the Antibodypedia initiative. This newsletter will bring you the latest news and metrics for Antibodypedia.
Antibody Validation - a community effort
We all know biological experiments can be tricky. Help other scientists by sharing your data and building a user community of comments, validations, and citations to the antibodies you have used in your research.
Last year the Affinity Binder Knockdown Initiative was launched. The initiative is a public-private partnership and uses crowdsourcing to gather target validation data for antibodies. For antibodies included in the initiative you can get rewarded for sharing your data.
Please read the recently published article to find out how we can collaborate in this program!
Have results you want to share? Please join us and submit your data!
Our media and methods pages
We published a mini-poster in Science that describes some of the most common techniques where antibodies are used.
Also visit our methods pages to read more about these techniques.
Send a request for the print version of the poster "The use of antibodies to study the human proteome" to contact@antibodypedia.com.
Antibodies and the human genome
At beginning of May 2016, Antibodypedia listed over 2.3 million antibodies, from 71 providers, targeting gene-products from 19 250 human ORFs (approx. 95% of the human genome).
Please let us know if you find discontinued products or outdated links so that we can keep the records up to date. Thanks!
Images and references
The antibodies in Antibodypedia are ranked based on the knowledge associated with them; a validation and citation score determines the rank and order in which the antibodies are listed.
The current antibody listing is supported with more than 1 million images and over a quarter of million references.
We are enthusiastic about reaching this milestone!
Our traffic
In Q1 of 2016, Antibodypedia received 51 179 visits, from 148 countries, comprising 145 834 page views. Just above half of the traffic originated in the United States (28%), Japan (8%), Germany (7%), United Kingdom (6%), or South Korea (5%).
Top gene visits
In Q1 of 2016, our five most-commonly-visited genes were TNF, PDCD1, EGFR, CD274, and A1BG. Cumulatively, these visits stood for 2.3% of all visited genes.
Get in touch!
Antibodypedia will be at these conferences during the year:
Come by our poster or send an email to arrange a meeting!
Please send us your feedback
What's frustrating? What changes would you like to see? And what are we getting right?
Contact us on contact@antibodypedia.com if you have any questions or thoughts on how we can improve our service to you.
And finally, I want to thank you for your interest in Antibodypedia.
Tove Alm
Manager Antibodypedia